Skin Cancer

The FDA has approved the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma.

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

The addition of bempegaldesleukin to nivolumab did not significantly improve progression-free survival, objective response rate, or overall survival vs nivolumab alone in the frontline treatment of patients with unresectable or metastatic melanoma, missing the primary end points of the phase 3 PIVOT IO-001 trial.

Merck announced that pembrolizumab led to significant improvement in distant metastasis-free survival (DMFS) compared to placebo as adjuvant therapy for patients with resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 trial.

The Mayo Clinic recently published a study examining the part of risk perception in curbing behavior that increases the risk of future melanoma.

Poster presented at Maui Derm for Dermatologists 2022 reveals prognostic value of 2 independently validated algorithms.

Melanoma in Black patients presents unique challenges for dermatologists due to clinical diagnostic differences, provider bias, and a lack of patient awareness, according to a presentation given at Maui Derm 2022.

In this week’s Pointers with Dr Portela, the 208SkinDoc dives into a social media video that shows someone advocating for urine for hair, skin, and overall body care. See what he has to say about this suggestion.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses the story of how a hockey fan spotted a cancerous mole on the on the Canucks, a National Hockey League (NHL) Team, equipment manager.

Skin cancer dermoscopy is getting a hightech overhaul as the scope of innovation broadens from a singular focus on the stand-alone product to the development of a comprehensive medical, patient care, and workflow management platform.

The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.

Skin cancer is on the rise. Knowing what teenagers and adolescents understand about protecting skin from the sun and how well they’re using that information can be important to changing that trend.

In this video interview we sit down with John Dobak, MD, and Laura Ferris, MD, PhD, to talk about DermTech, the TRUST study, and more.

Darrel S. Rigel, MD, highlights updates in photoprotection, sunscreen SPF levels, and oxybenzone.

In a video onsite at Fall Clinical Dermatology Conference, Darrell S. Rigel, MD, MS, highlights, in his own words, the potential of GEP as an adjunct to biopsy in melanoma detection.

How can GEP be applied to melanoma diagnosis and treatment? Darrel Rigel, MD, MS, answers these questions and dives into the data at Fall Clinical Dermatology Conference 2021.

Proscia announces new study data on artificial intelligence’s ability to detect melanoma.

The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.

Case-based observations offered clinicians real-world guidance on distinguishing underlying malignancies in the Therapeutic Hotline session at Maui Derm NP+PA Fall 2021.

Coppertone has issued a voluntary recall for 12 lots of its aerosol sunscreen, citing detected levels of the carcinogen benzene.

As a part of her Maui Derm NP+PA Fall 2021 presentation, Phoebe Rich, MD, discusses how different diseases manifest in the nails, including multiple patient examples, and whether or not biopsy is needed for diagnosis.

The EADV congress today presents new study data showing that skin cancer detection apps fail to correctly categorize rare and aggressive cancers as high-risk.

Possible melanoma treatments have had multiple newsworthy events since July 2021.

Bristol Myers Squibb has announced that the FDA has accepted the Biologics License Application (BLA) for relatlimab and nivolumab, a fixed-dose combination treatment for unresectable or metastatic melanoma.

DermTech’s Pigmented Lesion Assay data was published in SKIN: The Journal of Cutaneous Medicine showing the results of its melanoma detection.

The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.

Skin cancer rates have been increasing worldwide, and climate change factors – like depleting ozone layers – may be a factor.

It has been 20 years since the FDA approved a new sunscreen filter. However, a recent study evaluating curcumin could change that.

There are an increasing number of novel immunotherapies available for patients with skin cancer, however, their numerous adverse events must be addressed.

Curcumin has a long history as an effective treatment for everything from chronic pain to skin infections. Nanoparticle encapsulation shows promise in meeting that challenge and opening the way for a safe, effective adjuvant to sunscreen.